MarketCapExport financials
VBI Vaccines (VBIV)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
VBI Vaccines Balance Sheet 2023-2011 | VBIV
Brief overview of VBI Vaccines 's balance sheet structure
The review uses the five latest available annual reports between 2016 and 2020.
Assets rose from $104.8 million to $209.4 million, a gain of +99.9%, while CAGR was about 18.9%. The balance sheet expanded rapidly.
Liabilities increased less than assets, posting +79.2% versus +99.9%. That relationship usually strengthens the balance sheet.
Equity accounts for 82% of assets. Against the initial 79.9%, the capital position looks resilient.
Cash exceeds interest-bearing debt, producing net debt of -$76.6 million. The balance sheet therefore carries a net cash position.
Cash represents 44.8% of assets versus 30.8% initially, showing how the immediate liquidity reserve changed.
Retained earnings remain negative at -$308.6 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
What the balance sheet shows
VBI Vaccines shows a high-quality balance sheet profile, with adequate internal capital and room for maneuver.
Annual Balance Sheet VBI Vaccines
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
28.1 M | -12.8 M | -92.4 M | -76.6 M | -28.7 M | -45.2 M | -54.6 M | -20.3 M | -26.8 M | -37.7 M | -48.5 M | -37.7 M | -20.4 M |
Long Term Debt |
50.8 M | 48.9 M | 28.4 M | 16.3 M | 14.8 M | 12.9 M | 11.5 M | 12 M | - | - | - | - | - |
Long Term Debt Current |
976 K | 972 K | 839 K | 944 K | 642 K | 1.1 M | 1.6 M | - | - | - | - | - | - |
Total Non Current Liabilities |
3.69 M | 54 M | 33.8 M | 20.3 M | 4.19 M | 16.1 M | 12.6 M | 13.4 M | 1.92 M | - | - | - | 48.6 M |
Total Current Liabilities |
75.7 M | 36.9 M | 32.6 M | 17.3 M | 29.8 M | 23.4 M | 13.2 M | 7.61 M | 2.93 M | - | - | - | - |
Total Liabilities |
- | - | - | 37.7 M | 33.9 M | 39.5 M | 25.9 M | 21 M | 277 K | 249 K | 240 K | 710 K | 49.5 M |
Deferred Revenue |
7.28 M | 409 K | 526 K | 255 K | 882 K | 2.38 M | - | 34 K | - | - | - | - | - |
Retained Earnings |
-582 M | -490 M | -378 M | -309 M | -262 M | -208 M | -144 M | -105 M | -81.8 M | -65.7 M | -67.3 M | -63 M | -42 M |
Total Assets |
87 M | 155 M | 210 M | 209 M | 122 M | 138 M | 146 M | 105 M | 17 M | 157 M | 176 M | 185 M | 208 M |
Cash and Cash Equivalents |
23.7 M | 62.6 M | 122 M | 93.8 M | 44.2 M | 59.3 M | 67.7 M | 32.3 M | 12.5 M | 393 K | - | - | - |
Book Value |
87 M | 155 M | 210 M | 172 M | 88.3 M | 98.1 M | 120 M | 83.7 M | 16.8 M | 157 M | 175 M | 185 M | 158 M |
Total Shareholders Equity |
7.53 M | 64.2 M | 144 M | 172 M | 88.3 M | 98.1 M | 120 M | 83.7 M | 12.2 M | -9.43 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet VBI Vaccines
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
48.7 M | 50.8 M | 48.9 M | 47.8 M | 49.4 M | 48.9 M | 48.4 M | 21.2 M | 24.8 M | 28.4 M | 27.9 M | 27.5 M | 15.9 M | 16.3 M | 15.9 M | 15.4 M | 14.5 M | 14.8 M | 12.9 M | 12.9 M | 12.4 M | 12.9 M | 11.9 M | 12.5 M | 11.2 M | 11.5 M | 11.8 M | 12.1 M | 12.2 M | 12 M | - | 12 M | 12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
3.32 M | 3.69 M | 3.7 M | 51.9 M | 53.9 M | 54 M | 53.5 M | 26.1 M | 30.5 M | 33.8 M | 31.1 M | 30.5 M | 19.1 M | 20.3 M | 19.8 M | 19.4 M | 3.67 M | 4.19 M | 4.36 M | 3.82 M | 16.6 M | 16.1 M | 12.9 M | 13.6 M | 12.3 M | 12.6 M | 12.9 M | 13.2 M | 13.3 M | 13.4 M | - | 13.4 M | 13.4 M | 1.92 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
9.62 M | 7.28 M | 6.97 M | 845 K | 649 K | 409 K | 597 K | 864 K | 649 K | 526 K | 324 K | 885 K | 882 K | 255 K | 408 K | 742 K | 750 K | 882 K | 1.18 M | 2.1 M | 2.33 M | 2.38 M | 2.38 M | 2.38 M | 74 K | - | 34 K | 34 K | 34 K | 34 K | - | 34 K | 34 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-600 M | -582 M | -582 M | -562 M | -517 M | -490 M | -468 M | -443 M | -398 M | -378 M | -360 M | -344 M | -326 M | -309 M | -293 M | -280 M | -271 M | -262 M | -252 M | -235 M | -222 M | -208 M | -188 M | -173 M | -156 M | -144 M | -132 M | -123 M | -114 M | -105 M | - | -105 M | -105 M | -81.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
75.4 M | 87 M | 101 M | 88.3 M | 128 M | 155 M | 172 M | 172 M | 194 M | 210 M | 224 M | 225 M | 223 M | 209 M | 200 M | 161 M | 107 M | 122 M | 132 M | 115 M | 126 M | 138 M | 109 M | 120 M | 135 M | 146 M | 88.5 M | 92 M | 97 M | 105 M | - | 105 M | 105 M | 17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
12.6 M | 23.7 M | 35.5 M | 20.8 M | 40.4 M | 62.6 M | 83.6 M | 82.4 M | 101 M | 122 M | 137 M | 135 M | 108 M | 93.8 M | 95.2 M | 61 M | 35.8 M | 44.2 M | 53 M | 30.1 M | 43.3 M | 59.3 M | 26 M | 41.1 M | 58.1 M | 67.7 M | 10.1 M | 15.6 M | 23.5 M | 32.3 M | 16.7 M | 32.3 M | 32.3 M | 12.5 M | - | - | - | 393 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
75.4 M | 87 M | 101 M | 88.3 M | 128 M | 155 M | 172 M | 172 M | 194 M | 210 M | 224 M | 225 M | 223 M | 209 M | 200 M | 161 M | 107 M | 122 M | 132 M | 115 M | 126 M | 138 M | 109 M | 120 M | 135 M | 146 M | 88.5 M | 92 M | 97 M | 105 M | - | 105 M | 105 M | 17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-5.47 M | 7.53 M | 19.9 M | 8.74 M | 45 M | 64.2 M | 83.8 M | 106 M | 130 M | 144 M | 160 M | 168 M | 180 M | 172 M | 166 M | 127 M | 74.4 M | 88.3 M | 97.2 M | 76.3 M | 86.7 M | 98.1 M | 77.1 M | 89.8 M | 106 M | 120 M | 63 M | 69.4 M | 75.9 M | 83.7 M | - | 83.7 M | 83.7 M | 12.2 M | - | - | - | -9.43 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of VBI Vaccines , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
USA
Russia
Niderland
Israel
Spain
Germany
Australia
Britain
